Compare APYX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APYX | MDXH |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.0M | 149.0M |
| IPO Year | 1995 | 2021 |
| Metric | APYX | MDXH |
|---|---|---|
| Price | $3.68 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.50 | ★ $7.67 |
| AVG Volume (30 Days) | 123.2K | ★ 162.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.92 | $30.78 |
| Revenue Next Year | $10.08 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $1.36 |
| 52 Week High | $4.50 | $5.33 |
| Indicator | APYX | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 18.14 |
| Support Level | $3.27 | $1.90 |
| Resistance Level | $4.29 | $2.30 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 37.35 | 1.13 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.